Form 4 for BCAX Bicara Therapeutics Inc.
Accepted 2025-12-18 00:00:00 ET · period of report 2025-12-16 · accession 0002034671-25-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-18 | 2025-12-16 | BCAX | Mazumdar Claire | CEO, Dir | M - OptEx | $5.45 | +29.5K | 339.4K | +10% | +$160.8K |
| D | 2025-12-18 | 2025-12-16 | BCAX | Mazumdar Claire | CEO, Dir | M - OptEx | $0.00 | -29.5K | 565.5K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-16 | M | A | 29,500 | $5.45 | 339,392 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-12-16 | M | D | 29,500 | $0.00 | 565,512 | D | $5.45 · — to 2033-12-14 | 29,500 Common Stock | (F1) The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. |